Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stok Raporu

Piyasa değeri: US$665.6m

Entrada Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Entrada Therapeutics CEO'su Dipal Doshi, Aug2017 tarihinde atandı, in görev süresi 7.25 yıldır. in toplam yıllık tazminatı $ 3.74M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.7% maaş ve 84.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.35% ine doğrudan sahiptir ve bu hisseler $ 2.33M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 3.7 yıldır.

Anahtar bilgiler

Dipal Doshi

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi15.7%
CEO görev süresi7.3yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresi3.7yrs

Son yönetim güncellemeleri

Recent updates

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

CEO Tazminat Analizi

Dipal Doshi'un ücretlendirmesi Entrada Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$55m

Jun 30 2024n/an/a

US$104m

Mar 31 2024n/an/a

US$23m

Dec 31 2023US$4mUS$585k

-US$7m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$3mUS$565k

-US$95m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$6mUS$425k

-US$51m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$906kUS$385k

-US$27m

Tazminat ve Piyasa: Dipal 'ın toplam tazminatı ($USD 3.74M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.17M ).

Tazminat ve Kazançlar: Dipal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dipal Doshi (48 yo)

7.3yrs

Görev süresi

US$3,735,466

Tazminat

Mr. Dipal Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dipal Doshi
CEO & Director7.3yrsUS$3.74m0.35%
$ 2.3m
Nathan Dowden
President & COO5yrsUS$1.49m0.35%
$ 2.4m
Natarajan Sethuraman
President of Research & Developmentless than a yearUS$1.49m0.25%
$ 1.6m
Kory Wentworth
CFO & Treasurer4yrsVeri yok0.21%
$ 1.4m
Jared Cohen
General Counsel4.6yrsVeri yokVeri yok
Kerry Robert
Senior Vice President of People3.3yrsVeri yokVeri yok
Karla MacDonald
Chief Corporate Affairs Officer2.3yrsVeri yokVeri yok
Kevin Healy
Senior Vice President of Regulatory Affairsless than a yearVeri yokVeri yok

3.6yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: TRDA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dipal Doshi
CEO & Director7.3yrsUS$3.74m0.35%
$ 2.3m
Peter Kim
Director3.9yrsUS$192.12k0.29%
$ 2.0m
Mary Thistle
Industry Leader & Independent Director3.5yrsUS$211.18k0%
$ 0
Kush Parmar
Independent Chairman of the Board8.1yrsUS$237.58k0%
$ 0
Bernhardt G. Zeiher
Industry Leader & Independent Director1.6yrsUS$334.02k0%
$ 0
Gina Chapman
Independent Director1.2yrsUS$341.88k0%
$ 0

3.7yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TRDA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).